A Phase 2 interventional study of FX006 32 mg and TAcs 40 mg in Osteoarthritis of the Shoulder and Osteoarthritis of the Hip, sponsored by Pacira Pharmaceuticals, Inc. Completed at 6 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-01-24.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Osteoarthritis, Hip with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Osteoarthritis, Hip · United States.
Among the 155 studies in Osteoarthritis, Hip with a site in United States, this one is the 85th largest by enrollment of the 118 interventional ones that give a count, is one of 10 that started in 2017, is one of 10 in phase 2, and was the 72nd registered.
642 studies on the registry are indexed under Osteoarthritis, Hip; 121 are open to participants now.
Browse Osteoarthritis, Hip studies →21 of the 155 studies in Osteoarthritis, Hip with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18–75
Yale University · Sites in United States
Ages 18+
University of Sydney · Sites in United States, Australia
Ages 18+
Zimmer Biomet · Sites in United States
Ages 18+
F. Johannes Plate · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Osteoarthritis, Hip studies recruiting now, 54 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 18 · Phase 4 9
First in 2001; this study’s year is marked. 10 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 90 across 458 interventional studies indexed under Osteoarthritis, Hip.
Median enrollment 105 across the 118 interventional studies, 120 across the 34 observational. Of the 106 that completed or were terminated, 49 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 155 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 17 (63%) have results posted.
Pacira BioSciences, Inc. has 4 studies filed under Osteoarthritis, Hip — fewer than ten, so there is no comparison to draw.
5 of the studies in Osteoarthritis, Hip with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04990128Phase 3The Cleveland ClinicBone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis | 2027-10 |
| NCT06778486University of California, DavisConversations in Health Literacy Using AI Technology for Osteoarthritis Patients | 2026-12 |
| NCT05675618Hospital for Special Surgery, New YorkReturn to Golf After Orthopaedic Surgery | 2026-12 |
| NCT04039386Michael C WilleyPsychosocial Interventions for Young Adults With Hip Pain | 2027-08-01 |
| NCT07104084F. Johannes PlateInfluence of Antiseptic Washes on Wound Healing Complications After THA | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 155 studies in Osteoarthritis, Hip with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label study to compare systemic exposure to triamcinolone acetonide following a dose of extended-release FX006 or immediate-release TAcs (triamcinolone acetonide suspension) in patients with osteoarthritis of the shoulder (glenohumeral joint) or hip
This is a randomized, open-label, single dose study that will be conducted in male and female patients ≥40 years of age with OA of either the shoulder or the hip.
Approximately 24 patients with OA of the shoulder and approximately 24 patients with OA of the hip will be randomized to one of two treatment groups (1:1) and treated with a single IA injection of either:
Each patient will be screened to confirm the diagnosis of OA of either the shoulder or hip and eligibility based on the other inclusion/exclusion requirements and will be randomized to treatment on Day 1. Each patient will be evaluated for a total of 12 weeks following the IA injection. Following screening, sampling for pharmacokinetics (PK) and safety will be completed at 10 out-patient visits scheduled on Study Days 1 [calendar day of injection], 2, 3, 5, 8, 15, 22, 29, 57, and 85.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intra-articular (IA) injection of FX006 32 mg
Drug: FX006 32 mg
Single intra-articular (IA) injection of TAcs 40 mg
Drug: TAcs 40 mg
Extended-release 32 mg FX006 IA injection
Also known as: Zilretta
Immediate-release 40mg TAcs IA injection
Also known as: Kenalog®-40 Injection, Triamcinolone Acetonide Crystalline Suspension (TAcs), TCA-IR 40
Concentration of Triamcinolone Acetonide (TA) in Blood Plasma
Characterize the Pharmacokinetic Profile of FX006 and TCA IR \[Time Frame: Day 1 (pre-treatment,1, 2, 3, 4, 5, 6, 8,10, and 12 hrs. post-dose) and Days 2, 3, 5, 8, 15, 22, 29, 57,and 85\] For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations
Time frame: 12 Weeks
Total Number of Treatment Emergent Adverse Events
Analyses of adverse events (AE) were performed for events considered treatment-emergent (TE). TE was defined as any AE with onset after administration of the 1st dose of study drug or any event present at baseline but worsened in intensity through the study. Severity was graded by the PI using the Common Terminology Criteria for AEs Version 4.0. Grading went from Grade 1 (Mild) to Grade 5 (Death Related to AE).
Time frame: 12 Weeks
The recruitment period for this study was from December 2017 to July 2018. The patients were enrolled at medical clinics.
| Milestone | FX006 32 mg Shoulder | TAcs 40 mg Shoulder | FX006 32 mg Hip | TAcs 40 mg Hip |
|---|---|---|---|---|
| Started | 12 | 13 | 15 | 15 |
| Completed | 12 | 13 | 14 | 14 |
| Not completed | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
Characterize the Pharmacokinetic Profile of FX006 and TCA IR \[Time Frame: Day 1 (pre-treatment,1, 2, 3, 4, 5, 6, 8,10, and 12 hrs. post-dose) and Days 2, 3, 5, 8, 15, 22, 29, 57,and 85\] For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations
| pg/mL | FX006 32 mg Shoulder | TAcs 40 mg Shoulder | FX006 32 mg Hip | TAcs 40 mg Hip |
|---|---|---|---|---|
| Day 1 - Hour 1 | 1061.8 (819.95 to 1375.09) | 1104.1 (578.17 to 2108.52) | 681.8 (334.47 to 1389.69) | 3862.3 (2024.11 to 7370.02) |
| Day 1 - Hour 2 | 1117.6 (838.98 to 1488.62) | 1344.8 (682.40 to 2650.05) | 752.2 (364.55 to 1551.90) | 4052.4 (2134.61 to 7693.33) |
| Day 1 - Hour 3 | 1140.0 (849.77 to 1529.44) | 1501.8 (774.05 to 2913.69) | 748.0 (349.37 to 1601.44) | 4519.3 (2286.88 to 8930.88) |
| Day 1 - Hour 4 | 1142.4 (822.55 to 1586.49) | 1594.1 (856.43 to 2967.05) | 776.1 (352.73 to 1707.82) | 4557.8 (2362.49 to 8793.00) |
| Day 1 - Hour 5 | 1093.8 (759.94 to 1574.40) | 1662.7 (861.73 to 3208.09) | 792.9 (360.39 to 1744.51) | 4672.6 (2429.24 to 8987.65) |
| Day 1 - Hour 6 | 1052.8 (729.94 to 1518.37) | 1689.6 (893.53 to 3194.85) | 743.5 (331.07 to 1669.73) | 4469.8 (2393.87 to 8346.03) |
| Day 1 - Hour 8 | 1016.2 (702.66 to 1469.64) | 1668.3 (887.88 to 3134.86) | 705.0 (307.07 to 1618.77) | 4102.3 (2232.93 to 7536.76) |
| Day 1 - Hour 10 | 951.4 (670.78 to 1349.34) | 1506.3 (819.27 to 2769.61) | 698.2 (307.74 to 1583.97) | 3615.6 (2033.96 to 6427.30) |
| Day 1 - Hour 12 | 903.8 (637.58 to 1281.10) | 1531.3 (806.98 to 2905.65) | 675.1 (296.00 to 1539.62) | 3276.2 (1858.64 to 5775.00) |
| Day 2 - Hour 24 | 943.4 (690.74 to 1288.35) | 1467.0 (884.10 to 2434.35) | 791.0 (340.46 to 1837.60) | 3218.8 (1965.24 to 5272.05) |
| Day - 3 | 903.4 (639.75 to 1275.69) | 1413.1 (856.25 to 2332.05) | 682.1 (292.51 to 1590.60) | 1723.6 (1218.72 to 2437.70) |
| Day - 5 | 754.6 (536.22 to 1061.93) | 1038.2 (724.11 to 1488.44) | 562.4 (242.23 to 1305.93) | 897.3 (644.77 to 1248.66) |
| Day - 8 | 678.1 (497.82 to 923.66) | 857.8 (596.48 to 1233.52) | 472.3 (202.04 to 1103.90) | 525.3 (296.03 to 932.01) |
| Day - 15 | 397.6 (287.43 to 549.88) | 722.7 (574.45 to 909.25) | 382.6 (270.89 to 540.52) | 444.7 (278.24 to 710.85) |
| Day - 22 | 268.3 (186.53 to 385.82) | 476.7 (333.94 to 680.44) | 235.0 (170.80 to 323.29) | 331.6 (214.93 to 511.48) |
| Day - 29 | 201.0 (134.57 to 300.21) | 418.7 (300.39 to 583.66) | 256.3 (173.31 to 379.15) | 281.8 (179.32 to 442.91) |
| Day - 57 | 151.8 (92.60 to 248.73) | 200 (140.83 to 284.08) | 225.1 (156.31 to 324.15) | 133.1 (74.28 to 238.50) |
| Day - 85 | 100.1 (54.22 to 184.86) | 131.4 (64.14 to 269.25) | 112.0 (58.14 to 215.61) | 92.5 (51.16 to 167.11) |
Analyses of adverse events (AE) were performed for events considered treatment-emergent (TE). TE was defined as any AE with onset after administration of the 1st dose of study drug or any event present at baseline but worsened in intensity through the study. Severity was graded by the PI using the Common Terminology Criteria for AEs Version 4.0. Grading went from Grade 1 (Mild) to Grade 5 (Death Related to AE).
| Events | FX006 32 mg Shoulder | TAcs 40 mg Shoulder | FX006 32 mg Hip | TAcs 40 mg Hip |
|---|---|---|---|---|
| Total Number of Treatment Emergent Adverse Events | 10 | 7 | 8 | 17 |
Collected over Adverse events were collected following IA administration through the final study visit at 12 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FX006 32 mg Shoulder | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| TAcs 40 mg Shoulder | 0/13 (0%) | 0/13 (0%) | 3/13 (23.1%) |
| FX006 32 mg Hip | 0/15 (0%) | 0/15 (0%) | 4/15 (26.7%) |
| TAcs 40 mg Hip | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Event | FX006 32 mg Shoulder | TAcs 40 mg Shoulder | FX006 32 mg Hip | TAcs 40 mg Hip |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/12 | 0/13 | 0/15 | 1/15 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 0/13 | 1/15 | 2/15 |
| Influenza Like IllnessGeneral disorders | 1/12 | 0/13 | 0/15 | 0/15 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/12 | 0/13 | 1/15 | 1/15 |
| Urinary Tract InfectionInfections and infestations | 1/12 | 0/13 | 0/15 | 0/15 |
| Joint Range of Motion DecreasedMusculoskeletal and connective tissue disorders | 1/12 | 1/13 | 0/15 | 0/15 |
| Musculoskeletal DiscomfortMusculoskeletal and connective tissue disorders | 1/12 | 0/13 | 0/15 | 0/15 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 1/12 | 0/13 | 0/15 | 0/15 |
| Respiratory Tract CongestionRespiratory, thoracic and mediastinal disorders | 1/12 | 0/13 | 0/15 | 0/15 |
| Melanocytic HypoplasiaSkin and subcutaneous tissue disorders | 1/12 | 0/13 | 0/15 | 0/15 |
| Age, Continuous(years) | FX006 32 mg Shoulder | TAcs 40 mg Shoulder | FX006 32 mg Hip | TAcs 40 mg Hip | Total |
|---|---|---|---|---|---|
| Mean | 63.2 ± 11.39 | 61.9 ± 8.10 | 58.1 ± 7.60 | 60.1 ± 7.09 | 60.7 ± 8.53 |
| Sex: Female, Male(Participants) | FX006 32 mg Shoulder | TAcs 40 mg Shoulder | FX006 32 mg Hip | TAcs 40 mg Hip | Total |
|---|---|---|---|---|---|
| Female | 9 | 6 | 8 | 5 | 28 |
| Male | 3 | 7 | 7 | 10 | 27 |
| Ethnicity (NIH/OMB)(Participants) | FX006 32 mg Shoulder | TAcs 40 mg Shoulder | FX006 32 mg Hip | TAcs 40 mg Hip | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 1 | 1 | 5 |
| Not Hispanic or Latino | 9 | 13 | 14 | 14 | 50 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | FX006 32 mg Shoulder | TAcs 40 mg Shoulder | FX006 32 mg Hip | TAcs 40 mg Hip | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 2 | 5 | 5 | 13 |
| White | 10 | 11 | 8 | 9 | 38 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | FX006 32 mg Shoulder | TAcs 40 mg Shoulder | FX006 32 mg Hip | TAcs 40 mg Hip | Total |
|---|---|---|---|---|---|
| United States | 12 | 13 | 15 | 15 | 55 |
| Body Mass Index (BMI)(kg/mg^2) | FX006 32 mg Shoulder | TAcs 40 mg Shoulder | FX006 32 mg Hip | TAcs 40 mg Hip | Total |
|---|---|---|---|---|---|
| Mean | 28.9 ± 5.98 | 30.7 ± 3.59 | 29.3 ± 3.49 | 31.0 ± 4.40 | 30.01 ± 4.367 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in Oct 2018, 9 months.
Results were first posted in Dec 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FX006